A detailed smoking history and determination of
Immunotherapy
lung cancer
tobacco
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
entrez:
25
3
2020
pubmed:
25
3
2020
medline:
25
3
2020
Statut:
ppublish
Résumé
Although many studies have determined that PD-L1 expression by immunohistochemistry can be somewhat predictive of a response to checkpoint inhibitor the impact of specific genomic changes and smoking history in the context of PD-L1 expression is limited. This single-center study examined clinical and genomic factors beyond STK11 and EGFR in patients with advanced non-small cell lung cancer (NSCLC) to determine which patients benefit from therapy with immune checkpoint inhibitors (ICIs). Clinical and genomic features of patients with NSCLC treated with immunotherapy were compiled into a database. Genomic information collected included gene mutations via next generation sequencing, tumor mutation burden (TMB), and PD-L1 tumor proportional scores. A total of 131 patients with advanced NSCLC treated with ICIs were examined. Race was not associated with response. A positive response to immunotherapy was associated with smoke year increase (P=0.042). Among the clinical and genomic factors examined in this study, smoking status is the most predictive of response to ICIs. Only
Sections du résumé
BACKGROUND
BACKGROUND
Although many studies have determined that PD-L1 expression by immunohistochemistry can be somewhat predictive of a response to checkpoint inhibitor the impact of specific genomic changes and smoking history in the context of PD-L1 expression is limited. This single-center study examined clinical and genomic factors beyond STK11 and EGFR in patients with advanced non-small cell lung cancer (NSCLC) to determine which patients benefit from therapy with immune checkpoint inhibitors (ICIs).
METHODS
METHODS
Clinical and genomic features of patients with NSCLC treated with immunotherapy were compiled into a database. Genomic information collected included gene mutations via next generation sequencing, tumor mutation burden (TMB), and PD-L1 tumor proportional scores.
RESULTS
RESULTS
A total of 131 patients with advanced NSCLC treated with ICIs were examined. Race was not associated with response. A positive response to immunotherapy was associated with smoke year increase (P=0.042).
CONCLUSIONS
CONCLUSIONS
Among the clinical and genomic factors examined in this study, smoking status is the most predictive of response to ICIs. Only
Identifiants
pubmed: 32206553
doi: 10.21037/tlcr.2020.01.03
pii: tlcr-09-01-55
pmc: PMC7082292
doi:
Types de publication
Journal Article
Langues
eng
Pagination
55-60Informations de copyright
2020 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: A Dowlati—consulting or advisory role: Takeda, Abbvie, Seattle Genetics, Astra Zeneca, Bristol Myers Squibb; research funding: Loxo, Bayer, Incuron, Takeda, Regeneron, Tesaro, Amgen, Seattle Genetics, Symphogen, Abbvie, Ipsen. The other authors have no conflicts of interest to declare.
Références
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Cancer. 2019 Apr 1;125(7):1038-1049
pubmed: 30548240
ESMO Open. 2018 Oct 2;3(6):e000406
pubmed: 30305940
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
JAMA Oncol. 2017 Aug 1;3(8):1051-1058
pubmed: 28278348
Clin Cancer Res. 2016 Jul 1;22(13):3148-56
pubmed: 26861459
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
JAMA Oncol. 2016 Jan;2(1):46-54
pubmed: 26562159
Clin Cancer Res. 2016 Sep 15;22(18):4585-93
pubmed: 27225694
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Clin Oncol. 2015 Jun 20;33(18):2004-12
pubmed: 25897158
Cancer Med. 2019 Apr;8(4):1459-1466
pubmed: 30773851
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Blood. 2018 May 3;131(18):2007-2015
pubmed: 29514782
Clin Cancer Res. 2015 Jun 1;21(11):2613-23
pubmed: 25294902
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640